{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-277530","form_type":"8-K","ticker":null,"cik":"0001971543","company_name":"Mural Oncology plc","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.478986+00:00","generated_at":"2026-06-08T02:50:07.715587+00:00","sec_items":["1.01","2.01","3.03","5.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mural Oncology spins off from Alkermes with $275M funding; nemvaleukin trials readout in 1Q2025","bullets":["Spin-off completed Nov 15, 2023; Mural shares trade on Nasdaq under 'MURA' starting Nov 16.","$275M committed funding provides cash runway projected into 4Q 2025.","Lead candidate nemvaleukin in two potentially registrational trials; top-line data expected 1Q 2025.","Preclinical IL-18 and IL-12 programs; development candidate nominations planned in 2024.","Executive team includes CEO Caroline Loew, CFO Adam Cutler, CMO Vicki Goodman; board chaired by Scott Jackson."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-277530","json":"https://secwatch.observer/filing/0001193125-23-277530.json","markdown":"https://secwatch.observer/filing/0001193125-23-277530.md","text":"https://secwatch.observer/filing/0001193125-23-277530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/d319165d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:50:07.715587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22801e11a6","claim":"Caroline Loew, Ph.D. was elected as Chief Executive Officer at Mural Oncology plc.","evidence_excerpt":"In connection with the Separation, the following individuals were elected to the positions set forth in the table below: Name Position Caroline Loew, Ph.D. Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"5b7bcccf78","claim":"Caroline Loew, Ph.D. resigned as Principal Financial Officer and Principal Accounting Officer at Mural Oncology plc.","evidence_excerpt":"In connection with the Separation, Dr. Caroline Loew resigned as Principal Financial Officer and Principal Accounting Officer, effective as of November 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"f4448f1aeb","claim":"Adam Cutler was appointed as Principal Financial Officer and Principal Accounting Officer at Mural Oncology plc.","evidence_excerpt":"In connection with the Separation, Adam Cutler was appointed as Principal Financial Officer and Principal Accounting Officer, effective as of November 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"e8ac432ed73791b3e96dffa6b71b161718434bb5","claim":"Mural Oncology plc: Amended and restated Memorandum and Articles of Association (Constitution) (effective 2023-11-15).","evidence_excerpt":"The Memorandum and Articles of Association of Mural (the “Constitution”) was amended and restated, effective November 15, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-15"}],"fact_type":"governance_change"},{"claim_id":"a737f5e141a8f6e612ef3ff7d5dfd9982c03dd68","claim":"Mural Oncology plc completed a disposition involving Alkermes plc (closed 2023-11-15).","evidence_excerpt":"On November 15, 2023, Alkermes plc (“Alkermes”) completed the previously announced separation (the “Separation”) of its oncology business into Mural Oncology plc (“Mural”), a new, independent, publicly-traded company.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Alkermes plc"},{"label":"Closing","value":"2023-11-15"}],"fact_type":"ma_transaction"},{"claim_id":"3e5f55a63c9fcabaefa8eac45df1c25cf0839fda","claim":"Mural Oncology plc entered into Lease Assumption Agreement with Alkermes Subsidiary (effective 2023-11-13).","evidence_excerpt":"Alkermes Subsidiary entered into an assignment and assumption of lease agreement (the \"Lease Assumption Agreement\") with Mural Subsidiary, dated as of November 13, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"Alkermes Subsidiary"},{"label":"Effective","value":"2023-11-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}